| abstract |
Novel DKKl peptides and DKKl peptide-specific CTLs and associated methods for treating cancer and cancer-mediated disorders in a human or animal subject in need of such treatment by administering the peptide or CTLs alone or in combination to prevent or treat cancer are disclosed herein. The peptides and DKKl peptide-specific CTLs can be used alone, or in combination with other treatments, for the treatment of various cancers including ovarian, breast, colonic, brain, lung, prostate, pancreatic, lymphoma, esophageal carcinomas and melanoma. |